Next Investors logo grey

MMJ on the verge of cannabis production in Canada

Published 14-JAN-2016 11:50 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

MMJ Phytotech (ASX:MMJ) is one step closer to becoming a licensed grower of medical cannabis in Canada.

Having submitted its application last year, MMJ, which currently operates through its fully owned subsidiary, United Greeneries (UG), needs to obtain a ‘Marijuana for Medical Purposes Regulations (MMPR)’ license in order to commence growing operations in Canada.

Having received confirmation from Canada’s medical cannabis watchdog Health Canada (HC) that a ‘pre-license’ inspection of its Duncan Facility on Vancouver Island in British Columbia would take place on 1 February 2016, MMJ expects to have its license granted soon afterwards.

The inspection will take place onsite at the Duncan Facility over the course of two and half days and is designed to verify that the information submitted to HC is accurate. HC will also assess compliance with the applicable sections of the MMPR prior to license approval.

If and when the license is granted, UG will then immediately commence its growing operations which are currently targeting up to 1000kg of dried medical cannabis per year.

A green future

UG passing the permitting stage positions MMJ to become one of only a handful of producers in the world that are legally permitted to produce medical cannabis in a developed country within a stringent regulatory framework.

Andreas Gedeon, Managing Director of MMJ PhytoTech, sees the news as a significant milestone for MMJ.

“An MMPR license at the Duncan Facility will have enormous strategic and fundamental value,” Gideon said.

“Further, Duncan’s status as a Licensed Producer will be key to MMJ’s evolution into a diversified, revenue generating, integrated medical cannabis company.”

In Canada, MMJ has two facilities with pending applications – the Duncan Facility in Vancouver and the Lucky Lake Facility in Saskatchewan.

MMJ Duncan Facility

Duncan Facility in Vancouver, BC operated by United Greeneries, a subsidiary of MMJ Phytotech

Notice of pre-inspection is a key catalyst

In past cases, a pre-license inspection is the penultimate step before a license is granted with no known instances of a license being denied. Therefore, notice of a pre-license inspection can often be seen as de-facto approval in all but name.

Every MMPR applicant that has received a notice of Pre-License Inspection from HC has subsequently been issued an MMPR Licensed Producer license, making pre-inspection notices a value catalyst as opposed to the actual granting of a MMPR license.

The most recent example of this counter-intuitive status-quo was the recent pre-inspection announcement by Supreme Pharmaceuticals Inc (CSE:SL) on 3 December 2015. SL’s stock appreciated sharply by over 140% from C$0.20 per share at the time of the announcement to C$0.49 on 12 January 2016. SL has still not had its MMPR license granted as of yet.

The Duncan growing facility provides MMJ with a secure source of medical cannabis and brings MMJ close to near-term revenues from the sale of produce. MMJ plans to supply registered MMPR patients in Canada, other licensed producers in Canada or for export into other jurisdictions with medical cannabis regulations.

MMJ Phytotech is already listed on the Australian Stock Exchange (ASX), and is pursuing a ‘farm to pharma’ strategy of becoming a vertically integrated supplier of medical cannabis globally. MMJ completed its first sales in August last year and followed up with a wholesale sale agreement with a UK distributor in November 2015.

At the time of writing, MMJ shares were up 17.4% in early trade at $0.27 per share.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.